Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:ALT NASDAQ:GERN NASDAQ:KALA NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.92-1.0%$3.43$1.24▼$4.08$774.22M1.024.13 million shs2.48 million shsALTAltimmune$3.59-1.4%$3.83$2.90▼$11.16$316.85M0.183.64 million shs2.05 million shsGERNGeron$1.27$1.33$1.09▼$4.83$810.28M0.6311.99 million shs4.27 million shsKALAKALA BIO$19.25+3.4%$8.87$2.92▼$19.69$135.14M-1.82110,043 shs492,730 shsVRNAVerona Pharma PLC American Depositary Share$106.37-0.1%$104.80$27.54▼$106.45$9.17B0.142.17 million shs1.22 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-0.34%-9.23%-17.60%+102.05%ALTAltimmune0.00%-3.70%+0.28%-47.02%-53.81%GERNGeron0.00%-9.29%-12.41%-18.06%-71.84%KALAKALA BIO0.00%+27.97%+123.80%+329.03%+215.06%VRNAVerona Pharma PLC American Depositary Share0.00%+0.11%+1.10%+14.81%+257.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.92-1.0%$3.43$1.24▼$4.08$774.22M1.024.13 million shs2.48 million shsALTAltimmune$3.59-1.4%$3.83$2.90▼$11.16$316.85M0.183.64 million shs2.05 million shsGERNGeron$1.27$1.33$1.09▼$4.83$810.28M0.6311.99 million shs4.27 million shsKALAKALA BIO$19.25+3.4%$8.87$2.92▼$19.69$135.14M-1.82110,043 shs492,730 shsVRNAVerona Pharma PLC American Depositary Share$106.37-0.1%$104.80$27.54▼$106.45$9.17B0.142.17 million shs1.22 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-0.34%-9.23%-17.60%+102.05%ALTAltimmune0.00%-3.70%+0.28%-47.02%-53.81%GERNGeron0.00%-9.29%-12.41%-18.06%-71.84%KALAKALA BIO0.00%+27.97%+123.80%+329.03%+215.06%VRNAVerona Pharma PLC American Depositary Share0.00%+0.11%+1.10%+14.81%+257.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.00Buy$6.75131.16% UpsideALTAltimmune 2.57Moderate Buy$17.40384.68% UpsideGERNGeron 2.29Hold$3.79198.09% UpsideKALAKALA BIO 3.20Buy$21.7512.99% UpsideVRNAVerona Pharma PLC American Depositary Share 2.14Hold$109.002.47% UpsideCurrent Analyst Ratings BreakdownLatest ALT, VRNA, AKBA, GERN, and KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$15.00 ➝ $33.009/8/2025KALAKALA BIOMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$30.009/3/2025KALAKALA BIOLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/13/2025AKBAAkebia TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.008/8/2025VRNAVerona Pharma PLC American Depositary ShareZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.007/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$203.73M3.80N/AN/A($0.23) per share-12.70ALTAltimmune$20K15,842.67N/AN/A$1.74 per share2.06GERNGeron$164.45M4.93N/AN/A$0.46 per share2.76KALAKALA BIO$3.89M34.74N/AN/A$2.02 per share9.53VRNAVerona Pharma PLC American Depositary Share$42.28M216.84N/AN/A$2.56 per share41.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)ALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)GERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)KALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,545.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest ALT, VRNA, AKBA, GERN, and KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/A8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84ALTAltimmune0.0920.4420.44GERNGeron0.467.876.79KALAKALA BIO3.192.102.10VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ALTAltimmune78.05%GERNGeron73.71%KALAKALA BIO24.61%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ALTAltimmune4.40%GERNGeron7.42%KALAKALA BIO8.32%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.15 million257.19 millionOptionableALTAltimmune5088.26 million84.37 millionOptionableGERNGeron70638.02 million590.68 millionOptionableKALAKALA BIO307.02 million6.44 millionNot OptionableVRNAVerona Pharma PLC American Depositary Share3086.19 million82.06 millionOptionableALT, VRNA, AKBA, GERN, and KALA HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share $VRNA Shares Purchased by Millennium Management LLCSeptember 15 at 3:31 AM | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Shares Sold by Woodline Partners LPSeptember 13 at 4:36 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 12-Month High - Should You Buy?September 12 at 10:22 AM | marketbeat.comHere’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%September 12 at 8:51 AM | insidermonkey.comFred Alger Management LLC Lowers Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 12 at 5:20 AM | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Shares Sold by Octagon Capital Advisors LPSeptember 11, 2025 | marketbeat.comScientech Research LLC Takes Position in Verona Pharma PLC American Depositary Share $VRNASeptember 10, 2025 | marketbeat.comInvesco Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNASeptember 10, 2025 | marketbeat.comTemasek Holdings Private Ltd Makes New $2.01 Million Investment in Verona Pharma PLC American Depositary Share $VRNASeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Decreases Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 8, 2025 | marketbeat.comPolar Asset Management Partners Inc. Takes Position in Verona Pharma PLC American Depositary Share $VRNASeptember 8, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Shares Acquired by Duquesne Family Office LLCSeptember 6, 2025 | marketbeat.comEventide Asset Management LLC Reduces Stake in Verona Pharma PLC American Depositary Share $VRNASeptember 6, 2025 | marketbeat.comCinctive Capital Management LP Purchases New Position in Verona Pharma PLC American Depositary Share $VRNASeptember 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Stake Raised by Boothbay Fund Management LLCSeptember 6, 2025 | marketbeat.com160,000 Shares in Verona Pharma PLC American Depositary Share $VRNA Bought by Cutter Capital Management LPSeptember 6, 2025 | marketbeat.comAllostery Investments LP Invests $794,000 in Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Buys Shares of 139,067 Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 1-Year High - Here's What HappenedSeptember 5, 2025 | marketbeat.comState of Wyoming Invests $291,000 in Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Boosts Position in Verona Pharma PLC American Depositary Share $VRNASeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025Palo Alto Networks Uptrend Confirmed! New Highs Set by Year’s EndBy Thomas Hughes | August 19, 2025ALT, VRNA, AKBA, GERN, and KALA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.92 -0.03 (-1.02%) Closing price 04:00 PM EasternExtended Trading$2.95 +0.03 (+0.99%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Altimmune NASDAQ:ALT$3.59 -0.05 (-1.37%) Closing price 04:00 PM EasternExtended Trading$3.62 +0.03 (+0.70%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Geron NASDAQ:GERN$1.27 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.27 0.00 (0.00%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.KALA BIO NASDAQ:KALA$19.25 +0.63 (+3.38%) Closing price 04:00 PM EasternExtended Trading$18.58 -0.67 (-3.48%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$106.37 -0.06 (-0.06%) Closing price 04:00 PM EasternExtended Trading$105.72 -0.65 (-0.61%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
